These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Gaig C; Ezquerra M; Marti MJ; Muñoz E; Valldeoriola F; Tolosa E Arch Neurol; 2006 Mar; 63(3):377-82. PubMed ID: 16533964 [TBL] [Abstract][Full Text] [Related]
3. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Orr-Urtreger A; Shifrin C; Rozovski U; Rosner S; Bercovich D; Gurevich T; Yagev-More H; Bar-Shira A; Giladi N Neurology; 2007 Oct; 69(16):1595-602. PubMed ID: 17938369 [TBL] [Abstract][Full Text] [Related]
4. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia. Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990 [TBL] [Abstract][Full Text] [Related]
5. Frequency of the LRRK2 G2019S mutation in siblings with Parkinson's disease. Lesage S; Leclere L; Lohmann E; Borg M; Ruberg M; Dürr A; Brice A; Neurodegener Dis; 2007; 4(2-3):195-8. PubMed ID: 17596714 [TBL] [Abstract][Full Text] [Related]
6. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. Deng H; Le W; Guo Y; Hunter CB; Xie W; Huang M; Jankovic J J Neurol Sci; 2006 Dec; 251(1-2):102-6. PubMed ID: 17097110 [TBL] [Abstract][Full Text] [Related]
7. Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients. Floris G; Cannas A; Solla P; Murru MR; Tranquilli S; Corongiu D; Rolesu M; Cuccu S; Sardu C; Marrosu F; Marrosu MG Parkinsonism Relat Disord; 2009 May; 15(4):277-80. PubMed ID: 18805725 [TBL] [Abstract][Full Text] [Related]
8. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Clark LN; Wang Y; Karlins E; Saito L; Mejia-Santana H; Harris J; Louis ED; Cote LJ; Andrews H; Fahn S; Waters C; Ford B; Frucht S; Ottman R; Marder K Neurology; 2006 Nov; 67(10):1786-91. PubMed ID: 17050822 [TBL] [Abstract][Full Text] [Related]
9. Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease. Huang Y; Halliday GM; Vandebona H; Mellick GD; Mastaglia F; Stevens J; Kwok J; Garlepp M; Silburn PA; Horne MK; Kotschet K; Venn A; Rowe DB; Rubio JP; Sue CM Mov Disord; 2007 May; 22(7):982-9. PubMed ID: 17427941 [TBL] [Abstract][Full Text] [Related]
10. Clinical heterogeneity of the LRRK2 G2019S mutation. Papapetropoulos S; Singer C; Ross OA; Toft M; Johnson JL; Farrer MJ; Mash DC Arch Neurol; 2006 Sep; 63(9):1242-6. PubMed ID: 16966501 [TBL] [Abstract][Full Text] [Related]
11. Prevalence and clinical features of LRRK2 mutations in patients with Parkinson's disease in southern Spain. Gao L; Gómez-Garre P; Díaz-Corrales FJ; Carrillo F; Carballo M; Palomino A; Díaz-Martín J; Mejías R; Vime PJ; López-Barneo J; Mir P Eur J Neurol; 2009 Aug; 16(8):957-60. PubMed ID: 19473361 [TBL] [Abstract][Full Text] [Related]
12. High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal. Ferreira JJ; Guedes LC; Rosa MM; Coelho M; van Doeselaar M; Schweiger D; Di Fonzo A; Oostra BA; Sampaio C; Bonifati V Mov Disord; 2007 Jun; 22(8):1194-201. PubMed ID: 17469194 [TBL] [Abstract][Full Text] [Related]
13. [Clinical features of LRRK2-associated Parkinson's disease]. Pchelina SN; Ivanova ON; Emel'ianov AK; Iakimovskiĭ AF Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12):56-62. PubMed ID: 22433811 [TBL] [Abstract][Full Text] [Related]
14. Genetic screening for two LRRK2 mutations in French patients with idiopathic Parkinson's disease. Funalot B; Nichols WC; Pérez-Tur J; Mercier G; Lucotte G Genet Test; 2006; 10(4):290-3. PubMed ID: 17253937 [TBL] [Abstract][Full Text] [Related]
16. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868 [TBL] [Abstract][Full Text] [Related]
17. LRRK2 gene in Parkinson disease: mutation analysis and case control association study. Paisán-Ruíz C; Lang AE; Kawarai T; Sato C; Salehi-Rad S; Fisman GK; Al-Khairallah T; St George-Hyslop P; Singleton A; Rogaeva E Neurology; 2005 Sep; 65(5):696-700. PubMed ID: 16157901 [TBL] [Abstract][Full Text] [Related]
18. Low frequency of common LRRK2 mutations in Mexican patients with Parkinson's disease. Yescas P; López M; Monroy N; Boll MC; Rodríguez-Violante M; Rodríguez U; Ochoa A; Alonso ME Neurosci Lett; 2010 Nov; 485(2):79-82. PubMed ID: 20727385 [TBL] [Abstract][Full Text] [Related]
19. LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8. Nichols WC; Elsaesser VE; Pankratz N; Pauciulo MW; Marek DK; Halter CA; Rudolph A; Shults CW; Foroud T; Neurology; 2007 Oct; 69(18):1737-44. PubMed ID: 17804834 [TBL] [Abstract][Full Text] [Related]
20. G2019S LRRK2 mutation in familial and sporadic Parkinson's disease in Russia. Pchelina SN; Yakimovskii AF; Ivanova ON; Emelianov AK; Zakharchuk AH; Schwarzman AL Mov Disord; 2006 Dec; 21(12):2234-6. PubMed ID: 17044089 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]